LUCD Lucid Diagnostics Inc

$LUCD what makes EsoGuard unique is that it actually drives endoscopy revenue for GI clinics. When a patient has a positive EsoGuard test they almost always get an upper endoscopy. When they don’t use EsoGuard, they skip the endoscopy 90% of the time. The product absolutely sells itself. IMO we could see test volume and revenue ramp unlike any diagnostic test in history. Remember Cologuard was viewed by GI’s as “stealing” their lucrative endoscopy revenue. This is precisely the reverse. Clinics using EsoGuard are needing to hire new staff to keep up.

$LUCD Most people have a very reasonable expectation of what to expect tonight and tomorrow in here. It's nice to see levelheaded longs who get it. My expectation for tomorrow is this...ridiculously limited revenues. Some guidance...but limited. However, this will be the lowest revenue generating quarter of any moving forward. In fact, I expect quarter for quarter growth going forward from here on for at least 10 years.

$LUCD An LCD from CMS tomorrow would put us in the perfect 6 week meeting window of Dec 7-11th. It would satisfy the CMS requirement to report back within the response time. It dodges the Thanksgiving and Christmas holiday's...It gets it off the books before the end of the year. Wondering if we see an end of the day runup in anticipation. I didn't wait until the end of the day. Added 147,500 shares today in anticipation. I'm not the type that likes to buy after the news and chase at a higher price...I like to take advantage of bargain basement pricing. I'll be on a plane to Mexico very early in the morning...Hopefully I land with some amazing news for a very fun week ahead. Buena suerte mis amigos!!!

$LUCD The nonsense posted on here is entertaining. I now have most of my cash from selling long term Ardelyx parked here. With MoIDX MAC of CMS all but certain LCD at any time- we should see 5x plus in short order. Diagnostic companies easily kept at arm’s length until they can’t be. Quest. LabCorp. Agilent. Becton (BD), Shenzhen, etc. Medicare is a MUST for any company to survive with its products or they risk other insurers pulling support and fail to cover like Raab is losing Xphozah with $ARDX . (Ironically CEO of the year while he has no idea what he is doing). Easily my best investment and admittedly got lucky with all my 6-figure adds recently under 50¢. THIS WILL BE BIOPHARM STOCK OF THE DECADE position for me. Will it be yours also? Biggest TAM I’ve seen in a long while.

$LUCD I’m sure we’ll be overrun by penny stock pumpers again so things I’m watching this week - short interest as of 10/15 comes out tomorrow and I think we have a good shot at an LCD Wednesday night. Would also be nice to see some form 4s at these prices. At any time we could see coverage from Evicore and/or Carelon (following Concert’s lead). Smith real world evidence paper should also be out in the next week or two. Until next weekend…

$LUCD The disgruntled poster below invested in Eyepoint Pharmaceuticals. I warned investors at 18.00 per share the study results would unlikely pass their primary endpoint due to the lack of strength of the medication. They failed 2 consecutive studies and the stock went from 18.00 to .39. His anger should be directed toward the Eyepoint management, but he would rather cherry-pick a couple posts in a broad-based sector downturn. A handful of penny flippers get very aggressive on boards when you post facts that go against their agenda. still long here and cost avg is .70603 not concerned one bit...i'm VERY long....so not at all trying to sell anyone my shares as I'll be here a while

$LUCD - I know there are a lot of new eyes on the stock right now and a lot of swing traders that are looking for a quick profit. But as somebody who has been in the stock for a little while, and has followed the development of the current situation with Esoguard, I would encourage you to think about holding it for a little while longer. Over the next few months there are multiple catalysts that are going to happen as information gets released and management can speak about the current and future revenues and cash flows associated with this procedure. Not to mention getting full Medicare coverage (and claw back 12 months of test billing with no new associated expenses). As you have heard other posters say, the TAM is super significant and they are the only game in town on this one. You may want to hold just a little bit longer and try to get a little more alpha out of this one. My opinion only do your own due diligence, but I think you’ll be impressed 

$LUCD Castle is NOT doing any kind of non-endoscopic BE screening, they are only using Esopredict when Tissue Cypher tissue collection is inadequate, so there is absolutely no competitive threat here. See transcript from the call below (SR Protect or ISO Predict = Esopredict)

$LUCD For anyone new to LUCD, take note: "For a diagnostic test, a Total Addressable Market (TAM) is generally considered large if it exceeds $1 billion annually, with markets over $5 billion considered massive or blockbuster opportunities" "According to guidelines established by United States gastroenterology associations like the American Gastroenterological Association (AGA), the Total Addressable Market (TAM) for non-endoscopic screening tests for Barrett's Esophagus (BE) and Esophageal Adenocarcinoma (EAC) is estimated to be approximately $60 billion" Wake up people.

$LUCD Since we should be getting reimbursed for all medicare tests through the texas facility now, I view getting the LCD at this point mere icing on the cake. It took too long, but it's good to see the company got something right. At long last, we're basically a revenue based company. This upcoming CC ought to be a big deal. Can't wait to get some returns to show for sticking around from the PAVM days!

$LUCD Being able to buy this at these prices is like having a time machine and being able to go back and scoop up $EXAS at the same lows with prescience of the future. I bought EXAS for an average under $4 and sold it north of $25. I won't make the mistake of selling $LUCD early, this is going to be a hold until triple digit share prices. 500k shares long at 0.68, not selling until over $100.

$LUCD Either way I’m good tomorrow. If there is a sell off, just going to buy more. Panic selling creates buying opportunities for a long term investor. Making Money 101.

$LUCD I'm looking forward to a small run up before the ER. Very much looking forward to this ER and what they say about reimbursement and guidance and any other comments related to Moldx. Also interested if they post more new roles on LinkedIn. Will be a good sign for further expansion. Been here 5 years (previously owned pavm), can't let it go now. May add a few more shares in the 40s as well.

$LUCD Been reviewing the financial news. Medicare just started paying for this company’s cancer screening tests. PLUS they secured $15 MILLION in financing. Here’s what caught my attention. Medicare is funded by the government. The government can print money. So technically this company now has access to a customer that cannot run out of money. That’s a completely different revenue model than most small caps. I might have to classify this as a government-backed growth stock.

$LUCD why not a buy out as the test is validated and now reimbursed. A strategic player with a history of executing new product launches would be a great fit.

$LUCD this may help: you’ve got science, you’ve got a patient base, you’ve got doctors with their own economic incentives, and you have the payor that gets stuck with the bill. A procedure can either end up saving a payor money over the life of the covered patient or it can cost the payor way more money per patient. if the economic(for payor and for patient re deductible), and health outcome per patient are better using this test and the specialist actually make money on other procedures by using ESO guard, and unlike EXAS where are you send the patient home with a boxed test and hope they mail it in, with Sigurd, as soon as DOC does ESOGUARD, they’re getting paid on that test(unless the sample gets lost in transit), plus a positive result➡️more endoscopies➡️practice rev grows. I cannot find anybody that is not going to embrace this test and that’s the patient, the doctor and the payer. The only one that loses here is oncologists and the aggressive cancer treatment business.

$LUCD 38,000,000 shares. Forming a good base. Feeling good about where we are headed. GLTA.

$LUCD EXAS - "October 9, 2014: Final CMS National Coverage Determination (NCD) released, making Cologuard covered by Medicare immediately." EXAS revenue growth from 2013 through 2025...

$LUCD Remember...if the internet says it, it MUST be true... Yes, non-endoscopic tests for (BE) and (EAC) are expected to become significantly more popular in the future. Key Factors Driving Future Popularity • Overcoming Endoscopy Limitations: Traditional upper endoscopy (sedated EGD) is invasive, expensive, and limited by a shortage of trained specialists. Non-endoscopic alternatives offer office-based, low-cost, and better-tolerated testing. • Society Guideline Recognition: Major medical organizations—now recognize swallowable cell collection devices and biomarker panels as acceptable or conditional alternatives to traditional endoscopy for high-risk patients. ◦ Swallowable devices like EsoCheck and EsoGuard allow clinicians to collect esophageal cells in a quick office visit. • More than 80% of EAC cases are currently diagnosed after symptoms appear (when survival rates is below 20%), medical systems are shifting toward non-endoscopic screening.

$LUCD nice, 3q volume was nothing special as expected but record volume in October with more than 1800 tests. Remind you, they had been averaging 2500-3k per quarter until now.